Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-03-01
2011-03-01
Rooney, Nora M (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07897349
ABSTRACT:
The present invention relates to the association between detecting and quantifying the presence of macrophage migration inhibitory factor (MIF) in urine, bladder and prostate tissues for the purpose of diagnosis and prognosis of urological inflammatory. In addition, methods to inactivate MIF activity by use of antibodies or specific MIF inhibitors can be used to treat these diseases. For instance, such diseases as chronic pelvic pain syndrome, non-bacterial prostatitis, and interstitial cystitis may be mediated by MIF release. Periodic assays for MIF could be conducted for a patient to determine if the patient's MIF urine levels are high or increasing. In addition, intravesical MIF antibodies or other MIF-specific inhibitors would reduce or ameliorate these pelvic diseases.
REFERENCES:
patent: 5503986 (1996-04-01), Steers et al.
patent: 6008003 (1999-12-01), Haak-Frendscho et al.
patent: 6043044 (2000-03-01), Hudson et al.
patent: 2005/0054117 (2005-03-01), Giroir et al.
patent: WO 2004/076679 (2004-09-01), None
Vera et al. ‘Macrophage migration inhibitory factor is released as a complex with alpha1-inhibitor-3 in the intraluminal fluid during bladder inflammation in the rat.’ J. Urology. 174:338-343.
Joshi et al. ‘Trauma patients with positive cultures have higher levels of circulating macrophage migration inhibitory factor (MIF).’ Res. Comm. Molec. Path. Pharm. 107(1 & 2):13-20, 2000.
Meyer Siegler et al. ‘Intravesical antibody against macrophage migration inhibitory factor (MIF) reduced substance P induced inflammatory changes in the rat bladder.’ Program No. 608.8 2003 Abstract Viewer/Itenerary Planner Washington, DC: Society for Neuroscience, 2003.
Vera et al. ‘Macrophage migration inhibiory factor (MIF) is upregulated in viscero-visceral interactions at the organ and central nervous system levels.’ Program No. 608.9. 2003 Abstract Viewer/Itenerary Planner. Washington, DC:Society for Neuroscience, 2003.
Meyer-Siegler et al. ‘Proinflammatory cytokine upregulation in central and peripheral tissue innercation the bladder in an endotoxin induced model of rat bladder inflammation.’ Program No. 71.8. 2002 Abstract Viewer/Itenerary Planner. Washington, DC: Society for Neuroscience, 2002.
Vera et al. ‘Macrophage migration inhibitory factor (MIF) and cyclooxygenase-2 (COX-2) are upregulated in an acid-model of bladder inflammation in rats.’ Program No. 71.1. 2002 Abstract Viewer/Itenerary PLanner. Washington, DC: Society for Neuroscience, 2002.
Pollock et al. ‘Laboratory techniques for detection of urinary tract infetion and assessment of value.’ Am. J. Med. 75(1B):79-84, 1983.
Meyer-Siegler et al. ‘Macrophage migration inhibitory factor is increased in the urine of patients with urinary tract infection: macrophage migration inhibitory factor-protein complexes in human urine.’ J. Urol. 175:1523-1528, 2006.
Otukesh et al. ‘Urine macrophage migration inhibitory factor (MIF) in children with urinary tract infection: a possible predictor of acute pyelonephritis.’ Pediatr. Nephrol. Epub Sep. 18, 2008.
Otukesh et al. ‘Urine macrophage migration inhibitory factor in pediatric systemic lupus erythematosus.’ Clin. Rheumatol. 26:2105-2107, 2007.
Matsumoto et al. ‘Elevated macrophage migration inhibitory factor (MIF) levels in the urine of patients with focal glomerular sclerosis.’ Clin. Exp. Immunol. 139:338-347, 2004.
Brown et al. ‘Urine macrophage migration inhibitory factor reflects the severity of renal injury in human glomerulonephritis.’ J. Am. Soc. Nephrol. 13:S7-S13, 2002.
Brown et al. ‘Urine macrophage migration inhibitory factor concentrations as a diagnostic tool in human renal allograft rejection.’ 17(12):1777-1783, 2001.
Matsumoto et al. ‘Urinary levels of macrophage migration inhibitory factor in patients with IgA nephropathy.’ Nephron 92:309-315, 2002.
Chai et al. ‘Diagnosis of the painful bladder syndrome: current approaches to diagnosis.’ Clin. Obst. & Gynec. 45(1):250-258, 2002.
Erickson et al. ‘Urine Markers of Interstitial Cystitis.’ Urology 57(Suppl 6A): 15-21, 2001.
Fernandez et al. ‘Anatomical location of macrophage migration inhibitory factor in urogenital tissues, peripheral ganglia and lumbosacral spinal cord of the rat.’ Program No. 608.7 Abstract Viewer/Itinerary PLanner. Washington, DC: Society for Neuroscience, 2003.
Vera et al. ‘Anatomical location of macrophage migration inhibitory factor in urogenital tissues, peripheral ganglia and lumbosacral spinal cord of the rat.’ BMC Neuroscience 4:17, 2003.
Rivas et al. ‘Molecular marker for development of interstitial cystitis in rat model: isoactin gene expression.’ J. Urology. 157(5):1937-1940, 1997.
Meyer-Siegler et al. (2005). Substance P induced changes in CD74 and CD44 in the rat bladder. J. Urol. 173(2):615-620.
Vera et al. (2004). Inflamation of the rat prostate evolkes release of macrophage migration inhibitory factor in the bladder: evidence for a viscerovisveral reflex. J. Urol. 172:2440-2445.
Meyer-Siegler et al. (2004). Intraluminal antibodies to macrophage migration Inhibitory factor decrease substance P induced inflamatiory changes in the rat bladder and prostate. J. Urol. 172:1504-1509.
Vera et al. (2003). Hydrocloric acid induced changes in macrophage migration inhibitory factor in the bladder peripheral and central nervous system of the rat. J. Urol. 170:623-627.
Meyer-Siegler et al. (2004). Substance P induced release of macrophage migration inhibitory factor from rat bladder epithelium. J Urol. 171:1698-1703.
Meyer-Siegler et al. (2004). Macrophage migration inhibitory factor is upregulated in an endotoxin-induced model of bladder inflammation in rats. J Interferon & Cytokine Res. 24:55-63.
Siegler Katherine Meyer
Vera Pedro L.
Klarquist & Sparkman, LLP
Rooney Nora M
The United States of America as represented by the Department of
LandOfFree
Macrophage migration inhibitory factor (MIF) as marker for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Macrophage migration inhibitory factor (MIF) as marker for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Macrophage migration inhibitory factor (MIF) as marker for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2705098